The present and prospective situation of infliximab in treatment of Crohn's disease

Ying HAN,Shi-rong LI

2001-01-01

Abstract:Infliximab,an anti-TNF-α chimeric monoclonal anti body product,was approved by US FDA in 1998 for use in treatment of resistant Cr ohn's disease.The present and prospective situations of infliximab are reviewed by the authors

What problem does this paper attempt to address?

Biologic Therapy of Crohn’s Disease: Infliximab

Frank Hoentjen,Atsushi Sakuraba,Stephen Hanauer

DOI: https://doi.org/10.1007/978-1-4614-0998-4_33

2011-11-02

Abstract:Infliximab is a chimeric monoclonal antibody directed at tumor necrosis factor α that has numerous potential mechanisms of action in immune-mediated inflammatory disorders. In addition to neutralization of circulating TNF-α, infliximab binds to membrane bound TNF-α, induces apoptosis of lymphocytes and monocytes, impairs downstream cytokine signaling, and enhances production of metalloproteinases that contribute to wound healing. Infliximab is indicated for induction and maintenance of remission for patients with “moderate-severe” refractory (steroid-dependent, steroid-refractory, and immunosuppressive-refractory) and fistulizing Crohn’s disease, as well as for patients with intolerance to other immunosuppressive therapy. Infliximab is relatively safe, although the risk of infections (in particular infections due to intracellular pathogens) is significantly increased with concomitant steroid use and older age. The potential increased risk of lymphomas during infliximab therapy is debated and the risk of hepatosplenic T cell lymphomas is limited to young males, mostly receiving combination therapy. The formation of antibodies to infliximab is associated with infusion reactions (both acute and delayed) and decreased efficacy. Strategies for reducing the formation of antibodies to infliximab include scheduled (vs. episodic) treatment and concomitant immunosuppression. According to our current knowledge, combination therapy of infliximab with immunosuppressants, such as azathioprine or 6-mercaptopurine, leads to less antibody formation, higher trough levels, mucosal healing, higher steroid-free remission rates, and less surgery. Accumulating expertise regarding indications for infliximab, side effects, loss of response, and concomitant immunosuppression make infliximab a potent and relatively safe treatment option for Crohn’s disease. Future research is needed to determine the optimal positioning of biologics and strategies to maintain response to infliximab while minimizing the long-term risks of complications.
Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

Ling-na YE,Jing-jing XIA,Qian CAO

DOI: https://doi.org/10.3760/cma.j.issn.0254-1432.2013.12.012

2013-01-01

Abstract:Objective To evaluate the clinical efficacy and safety of iMliximab (IFX) in the treatment of Crohn's disease (CD).Methods From February 2009 to March 2013,the clinical data of 62 CD patients with IFX treatment were retrospectively analyzed.At week 14th after IFX injection and the end of follow-up of this study (March 2013) were two observation points.At week 14th after IFX injection (three times of IFX injection),C reactive protein (CRP) level,Crohn's disease activity index (CDAI) score and clinical remission were investigated.At the end of follow-up,clinical remission,fistula closure,mucosal healing and side effects were inspected.Normal distribution data were expressed as 2±s,which were compared with t test.Non normal distribution data were expressed as M (QL-QU) and compared with Wilcoxon test.Results Four cases without complete three times of IFX injection and one case lost to follow-up were eliminated.And nine postoperation cases with IFX treatment to prevent recurrence after surgery were excluded.A total of 48 cases of CD in active period were enrolled in this study on efficacy.At week 14th,CRP level of 48 patients [1.9(0.5,5.4) mg/L]decreased compared with that before treatment [28.9(6.4,51.1) mg/L] (Z=-5.468,P＜0.01);CDAI score (87.0±35.8) also decreased compared with that before treatment (245.1±59.1) (t=18.579,P＜0.01).At week 14th,46 patients in active period achieved clinical remission and the remission rate was 95.8％.By the end of follow-up,38 patients were still in remission period and the remission rate was 79.2％.Among 26 patients with anal fistula before IFX treatment,seven cases (26.9％) were completely closed,17 cases (65.4％) was partially closed and two cases was responseless.Fifteen patients were reviewed by colonoscopic examination after more than six times of IFX treatment.The median of simple endoscopic score for Crohn's disease (SES-CD) was 3 (0,5)after treatment,which decreased compared with that before treatment (8(7,9),Z=-3.306,P=0.001).Twenty-two of 48 cases in active period received,step-up strategy and 26 cases received with top-down strategy.At week 14th,20 cases (90.9％) of group with step-up strategy and 26 cases (100.0％) of group with top-down strategy were in remission period.By the end of follow-up,14 cases (63.6％) of group with step-up strategy and 24 cases (92.3％) of group with top down strategy maintained remission.Among 26 cases with anal fistula,two cases without response were treated with step-up strategy and seven cases with complete closure were all with top-down strategy.Among 62 patients,five had side effects,three of whom had acute infusion reaction,one had delayed infusion reaction and the other had anemia.Conclusions IFX had good clinical efficacy in controlling inflammation,inducing clinical remission,promoting fistula closure and mucosal healing in CD patients.For some CD patients with high risk,the initial top-down strategy showed good clinical efficacy.
Preliminary Study on Treatment of Crohn's Disease with Infliximab

FU Mingsheng,LIU Hongchun,CHEN Shiyao

DOI: https://doi.org/10.3969/j.issn.1008-7125.2011.01.008

2011-01-01

Abstract:Background:The incidence of Crohn's disease(CD) is increasing in recent years.Infliximab(IFX),an anti-tumor necrosis factor-α antibody,can enhance the healing of mucosal lesions in CD patients.Aims:To investigate the therapeutic effect of IFX on CD.Methods:Sixteen CD inpatients at Shanghai Zhongshan Hospital from July 2008 to June 2009 were enrolled.The severity of CD was evaluated by CDAI score,and the patients were divided into conventional therapy group and IFX group.Patients in the two groups were given mesalazine + prednisone and IFX,respectively.After 8-week treatment,CDAI score,WBC,ESR,CRP and ALB levels were compared between the two groups.Results:Eleven mild active CD patients received conventional therapy,while 5 moderate active CD patients were given IFX.All the patients attained clinical remission,however,2 mild active patients with anal fistula turned to IFX after failure of conventional therapy and remission was then attained.After treatment,CDAI score,ESR and CRP levels were improved in both two groups(P<0.05),however,the lowering of CDAI score in IFX group was significantly higher than that in conventional therapy group(P=0.019).Conclusions:IFX is superior to conventional therapy for inducing clinical remission in CD,and can enhance the healing of anal fistula if conventional therapy fails.
Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature

Maria P Vallejo,Arturo P Jaramillo,Carlos Luis Guanín Cabrera,Maria G Cueva,Mario Navarro Grijalva,Xavier Grandes

DOI: https://doi.org/10.7759/cureus.65971

2024-08-01

Cureus

Abstract:The introduction of steroid therapy in 1955 markedly decreased the mortality rate of severe ulcerative colitis (UC) from 24% in the placebo group to 7%, and it is currently less than 1% in specialist centers. Despite this advancement, the response of severe UC to steroids has stagnated over the past 50 years, with a high rate of colectomy persisting for severe to moderately severe cases. Infliximab (IFX) (Remicade, Centocor Inc., Malvern, PA, United States), an intravenously administered chimeric monoclonal immunoglobulin G1 antibody targeting tumor necrosis factor-alpha (TNF-α), has shown efficacy in numerous randomized controlled trials for treating moderate to severe and fistulizing Crohn's disease, particularly in patients unresponsive to conventional therapies. This led to its approval by the US Food and Drug Administration in 1998 for treating active and fistulizing Crohn's disease. Most clinical research on IFX has focused on Crohn's disease, which is characterized as a Th1-type condition driven by pro-inflammatory cytokines like TNF-α. Conversely, UC has traditionally been viewed as a Th2-type condition where TNF-α plays a lesser role. However, recent studies indicate that TNF-α might also contribute to the pathogenesis of UC. These findings highlight the necessity for larger randomized controlled trials to further investigate the benefits of therapies like IFX, with the ultimate goal of improving treatment outcomes and quality of life for patients with inflammatory bowel disease.
Safety of Infliximab During Perioperative Period in Crohn Disease Patients

REN Hua-jian,REN Jian-an

DOI: https://doi.org/10.3760/cma.j.issn.1673-4203.2012.10.019

2012-01-01

Abstract:With the appearance of new biological agents represented by infliximab,the medical therapy of crohns' disease has made breakthrough of progress.However,the controversial still remains about the use of infliximab during perioperative period in Crohn's disease patients.The aim of this article is to explore the influence of infliximab on postoperative complications in Crohn's disease patients.
Infliximab in the Treatment of Crohn's Disease: A User's Guide for Clinicians

William J. Sandborn,Stephen B. Hanauer

DOI: https://doi.org/10.1111/j.1572-0241.2002.07093.x

2002-12-01

Abstract:Induction therapy with infliximab is indicated for treatment of signs and symptoms, and induction and maintenance of remission in patients with moderate to severely active inflammatory Crohn's disease with an inadequate response to conventional therapy, and for reduction in the number of draining fistulas in patients with fistulizing Crohn's disease. Emerging indications for infliximab therapy in patients with Crohn's disease include maintenance of fistula improvement (reduction in the number of draining perianal or enterocutaneous fistulas) and complete fistula response (no draining fistulas) in patients with fistulizing Crohn's disease, steroid sparing in steroid-treated patients, early use in hospitalized patients who have not failed conventional medical therapy where there is either a severe clinical presentation or a rapid onset of action is desired, and in a variety of unusual and extra-intestinal manifestations of Crohn's disease. An infliximab dose of 5 mg/kg is recommended initally, but some patients who require maintenance dosing may benefit from increasing the infliximab dose over a range of 5-10 mg/kg. An induction regimen of 3 doses at 0, 2, and 6 weeks is the preferred dosing strategy for inducing remission. The optimal dosing interval for patients who require retreatment appears to be every 8 weeks for most patients. Concomitant immunosuppressive therapy with azathioprine, 6-mercaptopurine, or methotrexate may result in improved outcomes due to a reduction in the frequency of human anti-chimeric antibody formation, acute infusion reactions, and a reduced risk of delayed hypersensitivity-like reactions and formation of antinuclear antibodies. Pretreatment with diphenhydramine (and in selected cases of acetaminophen and, rarely, corticosteroids) is recommended in patients with a history of infusion reactions and patients at risk for delayed hypersensitivity-like reactions. Patients with evidence of active infection should not receive infliximab until the infection is adequately treated, and all patients should be screened for tuberculosis prior to initiating infliximab therapy.

gastroenterology & hepatology
Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Wang Kan,Ye Lingna,Pan Yipeng,Liu Weili,Cao Qian

DOI: https://doi.org/10.3760/cma.j.issn.0254-1432.2019.08.012

2019-01-01

Abstract:Objective To assess the safety of infliximab (IFX) treatment in patients with Crohn's disease(CD).Methods From January 2009 to May 2018,at inflammatory bowel disease (IBD) center of Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,486 CD patients received the treatment of IFX were enrolled and their clinical data were collected.Univariate and multivariate regression of binary logistic were performed for statistical analysis.Results The median follow-up duration was 31.1 months (12.0 months to 40.0 months).The median duration of IFX therapy was 13.0 months (7.0 months to 21.0 months).Among 486 patients,98 (20.16％) patients reported adverse effects,and 12 (2.47％) patients discontinued the therapy because of adverse effects.Acute infusion reaction was the most common adverse effect in CD patients who received IFX treatment accounting for 41.84％ (41/98) of all the adverse effects,and the incidence was 8.44％.Thirty-nine patients had mild and moderate infusion reaction,and all improved after symptomatic treatment (eight patients discontinued IFX therapy because of recurrent infusion reaction).Two patients developed severe infusion reaction as allergic shock,and both relieved after emergency rescue.Four patients developed late-phase allergic reactions.Among 486 patients,39 (8.02％) patients had infections,including infections of Clostridium difficile,cytomegalovirus,herpeszoster virus,Mycobacterium tuberculosis,and other opportunistic pathogens.There was no cases of infection related death.Thirty-six patients continued with IFX treatment after infection controlled.Among 486 patients,14 (2.88％) patients had severe infection,and all the cases improved after anti-infection treatment.Twenty-seven CD patients with hepatitis B virus (HBV) infection received anti-viral treatments,no active HBV infection was observed.Colon adenocarcinoma was found in one patient under colonoscopy at 22 months after discontinuation of IFX therapy.There were six patients with the history of benign tumors,and no evidence of recurrence,progress or malignancy during treatment.In terms of other rare adverse effects in 486 patients,there were eight (1.64％) patients with liver function injury,two (0.41％) patients with anemia,one (0.21％) patient with peripheral neuropathy,and four (0.82％) patients with skin lesion.Prolonged duration of IFX therapy,without combination of immune-suppressors and with increased baseline body mass index (BMI) were the risk factors of acute infusion reactions.Prolonged duration of IFX therapy and with low baseline albumin level were the risk factors of infections.Conclusions IFX is generally safe as the treatment for CD patients,and its adverse effects can be clinically controlled.Screening before therapy and monitoring during therapy may reduce the risks of adverse effects.
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease

Amy Hemperly,Niels Vande Casteele

DOI: https://doi.org/10.1007/s40262-017-0627-0

2018-01-12

Clinical Pharmacokinetics

Abstract:Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). It has been shown to induce and maintain both clinical remission and mucosal healing in pediatric and adult patients with inflammatory bowel disease (IBD) who are unresponsive or refractory to conventional therapies. The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of infliximab is low and at steady state ranges from 4.5 to 6 L. Therapeutic monoclonal antibodies, such as immunoglobulins, are cleared from the circulation primarily by catabolism. Median infliximab half-life is approximately 14 days. Infliximab concentration–time data in patients with CD and UC have been shown to be highly variable within an individual patient over time and between individuals by multiple population pharmacokinetic models. Covariates that have been identified to account for a part of the observed inter- and intra-individual variability in clearance are the presence of antidrug antibodies, use of concomitant immunomodulators, degree of systemic inflammation, serum albumin concentration, and body weight, which can affect the pharmacodynamic response. This article provides a comprehensive review of the clinical pharmacokinetics and pharmacodynamics of infliximab, as well as the role of therapeutic drug monitoring in the treatment of IBD.

pharmacology & pharmacy
P-030 Infliximab and Tuberculosis Infection

Jianfeng Cheng,Qian Cao

DOI: https://doi.org/10.1097/01.mib.0000438671.06875.b7

2013-01-01

Inflammatory Bowel Diseases

Abstract:Infliximab is an effective treatment for both inflammatory bowel disease and rheumatoid arthritis. However, it can increase the risk of infection. This study is aimed to investigate infliximab and tuberculosis infection. Literature searches in PUBMED, MEDLINE and EMBASE databases were performed. Randomized controlled trials with over 95% of the patients older than 18 years-old were included. Meta-analysis was performed to investigate the incidence, characteristics and mortality of tuberculosis after infliximab infusion. Forty-six relevant RCTs were included. Infliximab related tuberculosis cumulative incidence rate is 370/100,000(95% CI: 244–496/100,000), with incidence rate of 259/100,000 person years (95% CI: 145–373/100,000 person years). The underlying disease has an impact on the infliximab related tuberculosis incidence rate. Cumulative incidence rate of tuberculosis for rheumatoid arthritis is 499/100,000(95% CI: 261–726) and for inflammatory bowel disease is 287/100,000(95% CI: 33–541/100,000). There is a wide range of time frame from the first infusion to the incidence of TB (1–118 weeks). The infliximab related TBs are more extra-pulmonary (Pulmonary TB versus extra-pulmonary: 34% versus 57%). Among the 46 studies, 19 patients who developed TB after infliximab infusion died with cumulative mortality 0.46% (95% CI: 0.38%–0.54%), however, overall mortality rate is 15.1% (95% CI: 8.8%–21.3%) for patients with tuberculosis. Compared with the baseline of tuberculosis incidence rate (0.9–0.95/100,000), infliximab infusion obviously increases the TB incidence rate. The time to TB infection from the first infusion time has a very wide range, but most of the incidence is within 3 months from the first infusion. The mortality from infliximab related tuberculosis is higher than infliximab infusion without tuberculosis complications.
Crohn’s Disease with Infliximab Treatment Complicated by Rapidly Progressing Colorectal Cancer: A Case Report

Lin Xiao,Lie Sun,Kang Zhao,Yi-Sheng Pan

DOI: https://doi.org/10.4251/wjgo.v13.i4.305

2021-01-01

World Journal of Gastrointestinal Oncology

Abstract:BACKGROUND:Crohn's disease (CD) causes a range of digestive symptoms including recurrent diarrhea, abdominalgia, and flatulence, and severely impacts the quality of life of patients. Infliximab, a monoclonal antibody against tumor necrosis factor alpha, has recently been promoted as a therapeutic treatment for CD, but its safety margins remain uncertain. We report a case of rapidly progressive colorectal cancer that was diagnosed in a patient with CD who had previously been treated with infliximab.CASE SUMMARY:This case report refers to a 40-year-old male with a 6-year history of CD. The patient underwent transverse colostomy because of inflammatory ileus in 2017. He subsequently received infliximab treatment in 2018. Ten months later, worsening contracture of the transverse colostomy was observed. Imaging tests indicated that the patient may have developed colon cancer with extensive peritoneal implantation. At the same time, colonoscopy revealed a rectal mass and pathological examination indicated well-differentiated adenocarcinoma. Palliative ileostomy was performed to improve defecation in 2019. During the operation, a small nodular mass in the mesentery of the small intestine was identified and pathological examination of the mass revealed advanced adenocarcinoma. The patient was diagnosed with advanced colorectal cancer and administered palliative chemotherapy. He died in June 2020.CONCLUSION:We stress the importance of recognizing the possible occurrence of malignance in patients with CD receiving infliximab.
Application and Development of Anti-Tumor Necrosis Factor Therapies in Crohn Disease

Qin Du

2006-01-01

Abstract:Crohn disease (CD) is related with a complex interplay among genetic, immune and microbial factors. In recent years, many effective biological treatments have been used in CD. Tumor necrosis factor (TNF) is a significant immune mediator and proinflammatory factor, its role in the mechanism of CD has been realized more and more. In the article we review the application of several effective anti-TNF biologic agents in CD. Infliximab is the only US Food and Drug Administration (FDA) approved biologic agent for the treatment of CD by far, other treatments need more data to confirm their effect.
Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Haotian Chen,Jihao Shi,Yipeng Pan,Zhou Zhang,Hao Fang,Ying Chen,Wendong Chen,Qian Cao

DOI: https://doi.org/10.1007/s12325-019-01150-x

2019-01-01

Advances in Therapy

Abstract:To assess the cost-effectiveness of reimbursing infliximab for moderate-to-severe Crohn’s disease (MS-CD) in China from the perspective of public insurance payers.
Different Therapeutic Approaches on Quality of Life in Patients with Inflammatory Bowel Disease

Junjie Xu,Hui Lin,Xu Feng,Minyue Tang,Jun Shen,Zhihua Ran

DOI: https://doi.org/10.1186/s12876-014-0199-5

2014-01-01

BMC Gastroenterology

Abstract:Background: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.Methods: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.Results: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).Conclusions: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.
Infliximab Monotherapy for Chinese Patients with Moderate to Severe Plaque Psoriasis: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial.

Yang Hai-zhen,Wang Ke,Jin Hong-zhong,Gao Tian-wen,Xiao Sheng-xiang,Xu Jin-hua,Wang Bao-xi,Zhang Fu-ren,Li Chun-yang,Liu Xiao-ming,Tu Cai-xia,Ji Su-zhen,Shen Yang,Zhu Xue-jun

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.11.001

2012-01-01

Abstract:Background Tumor necrosis factor-a is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-a. The purpose of this study was to validate the efficacy and safety of 5 mg/kg infliximab therapy in Chinese patients with moderate to severe plaque psoriasis.Methods In this multicenter, double-blind, placebo-controlled trial, 129 patients with moderate-to-severe psoriasis were randomized to the induction therapy (weeks 0, 2 and 6) with infliximab 5 mg/kg (n=84) or placebo (n=45), followed with infliximab 5 mg/kg scheduled at week 14 and week 22 in the infliximab group, and infliximab 5 mg/kg scheduled at weeks 10, 12 and 16 in the placebo group. The primary end point was the proportion of patients who achieved at least 75% improvement in Psoriasis Area and Severity Index (PASI 75 response rate) from baseline at week 10.Results At week 10, 81.0% of patients treated with infliximab (5 mg/kg) achieved a 75% or greater improvement compared with 2.2% of patients treated with placebo (P <0.001). A significant improvement in PASI, Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), was seen from week 6 through week 14 in the infliximab group compared with the placebo group. Through week 22, PASI, PGA, DLQI were well maintained. The incidence of adverse events for the infliximab treatment group was slightly higher in comparison to the placebo treatment group during the first 10 weeks without statistical significance. However, there were 3 cases of tuberculosis that developed during the 26 weeks treatment with infliximal.Conclusions Infliximab treatment was effective as induction and maintenance treatments for Chinese patients with moderate to severe plaque psoriasis. Most drug-induced adverse events were mild to moderate, and well tolerated. Screening for tuberculosis is essential and prophylactic treatment should be given if necessary. Chin Med J 2012;125(11):1845-1851
Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

Florenzo Iannone,Fabrizio Conti,Alberto Cauli,Alberto Farina,Roberto Caporali

DOI: https://doi.org/10.2147/JIR.S240593

IF: 4.5

2022-06-01

Journal of Inflammation Research

Abstract:Florenzo Iannone, 1 Fabrizio Conti, 2 Alberto Cauli, 3 Alberto Farina, 4 Roberto Caporali 5 1 Rheumatology Unit, Department of Emergency and Organ Transplantation, Università Degli Studi Di Bari Aldo Moro, Bari, Italy; 2 Rheumatology Unit, Department of Clinical, Internal, Anesthetic and Cardiovascular Sciences, Sapienza Università di Roma, Rome, Italy; 3 Rheumatology Unit, Department of Medical Sciences and Public Health, AOU and University of Cagliari, Monserrato, Italy; 4 Medical Affairs Department, Celltrion Healthcare Italy srl, Milan, Italy; 5 Department of Clinical Sciences and Community Health, Research Centre for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy Correspondence: Florenzo Iannone, Rheumatology Unit, Department of Emergency and Organ Transplantation, Università Degli Studi Di Bari Aldo Moro, 11, Piazza Giulio Cesare, Bari (BA), 70124, Italy, Tel +39 080 5592775, Fax +39 080 5478802, Email The first subcutaneous (SC) formulation of infliximab CT-P13 has been authorized for the treatment of rheumatoid arthritis (RA) in Europe in 2019. Later, in 2020, approved indications were extended also to ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease (CD) and ulcerative colitis (UC). The present review provides summary of the key features of SC infliximab, with particular focus on pharmacokinetic profile, clinical development program in comparison with the intravenous (IV) formulation, and the latest evidence in the literature. We conclude that SC infliximab represents a new and promising approach in the treatment of patients with RA, offering an optimized clinical profile and a more practical option in comparison to the IV formulation. Nevertheless, SC formulation can improve the use of national health systems resources (e.g., through the time of healthcare workers not having to supervise infusions) and facilitate social distancing measures during the COVID-19 pandemic, as the patient can self-inject the medicine at home without going to the hospital. The limitations of the SC infliximab are mainly due to the limited experience of use in clinical practice and the absence of long-term drug retention data. Keywords: rheumatoid arthritis, TNF inhibitors, infliximab, subcutaneous, intravenous, SC, IV, RA Rheumatoid arthritis (RA) is an immune mediated inflammatory disease affecting around 20 million people worldwide. 1 Symptoms are usually represented by joint pain, swelling and stiffness, which can lead to joint damage and irreversible disability. 2–5 RA patients, compared to general population, show higher rates of disability, and frequently have a reduced work productivity, as well as health-related quality of life (HRQoL). 6–8 The wide spread of the disease and the burden of its symptoms make RA a relevant global public health issue. Medical treatment, including drug therapy, is a well-established option in the management of RA, having its primary goal in sustained clinical remission of patients. Low disease activity can be considered an alternative target, in particular for patients with a long duration of illness. 9,10 European League Against Rheumatism (EULAR) recommends starting treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) early after diagnosis of RA. In case treatment target is not achieved with initial treatment with a csDMARD and poor prognostic factors are present, it is recommended to add a biologic DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARDs). 9 bDMARDs include different classes depending on their mechanism of action. Among them, tumor necrosis factor (TNF) inhibitors were the first to enter clinical practice in the late 1990s and early 2000s, but still represent an effective and widely used option to switch disease activity off and halt structural joint damage. Currently authorized TNF inhibitors for the treatment of RA include adalimumab, certolizumab pegol, etanercept, golimumab, infliximab. This class was also the first to receive approval in Europe for a biosimilar medicine: infliximab in 2013. 11 In the same class, biosimilars of etanercept and adalimumab have been authorized since 2016 and 2017, respectively. 12,13 Overall, TNF inhibitors biosimilars contributed to make the use of this class more sustainable for national health systems and broaden access to therapy: in Italy, since their introduction in clinical practice in 2015, to 2020, the overall expenditure has reduced from 648M € to 347M €, and the number of Defined Daily Doses (DDD) administered per 1000 inhabitants per day has grown from 1.0 to 1.36. 14,15 Until the approval of the first subcutaneous (SC) formulation of infliximab in 201 -Abstract Truncated-

immunology
Optimized timing of using infliximab in perianal fistulizing Crohn's disease

Xue-Liang Sun,Shi-Yi Chen,Shan-Shan Tao,Li-Chao Qiao,Hong-Jin Chen,Bo-Lin Yang

DOI: https://doi.org/10.3748/wjg.v26.i14.1554

IF: 5.374

2020-04-14

World Journal of Gastroenterology

Abstract:Infliximab (IFX), as a drug of first-line therapy, can alter the natural progression of Crohn's disease (CD), promote mucosal healing and reduce complications, hospitalizations, and the incidence of surgery. Perianal fistulas are responsible for the refractoriness of CD and represent a more aggressive disease. IFX has been demonstrated as the most effective drug for the treatment of perianal fistulizing CD. Unfortunately, a significant proportion of patients only partially respond to IFX, and optimization of the therapeutic strategy may increase clinical remission. There is a significant association between serum drug concentrations and the rates of fistula healing. Higher IFX levels during induction are associated with a complete fistula response in these patients. Given the apparent relapse of perianal fistulizing CD, maintenance therapy with IFX over a longer period seems to be more beneficial. It appears that patients without deep remission are at an increased risk of relapse after stopping anti-tumor necrosis factor agents. Thus, only patients in prolonged clinical remission should be considered for withdrawal of IFX treatment when biomarker and endoscopic remission is demonstrated, especially when the hyperintense signals of fistulas on T2-weighed images have disappeared on magnetic resonance imaging. Fundamentally, the optimal timing of IFX use is highly individualized and should be determined by a multidisciplinary team.

gastroenterology & hepatology
Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease

Xin Li,Sha Fang,Yang Yu,Hongyu Yang,Yuefeng Rao,Dongsheng Hong,Chao Lu,Mengli Yu,Xiaoyang Lu,Chaohui Yu,Qingwei Zhao

DOI: https://doi.org/10.1016/j.cej.2022.136438

IF: 15.1

2022-01-01

Chemical Engineering Journal

Abstract:Although the strategy for administering antibodies orally for inflammatory bowel disease (IBD) treatment has been proposed, the rational design for efficient delivery system is still a challenge, restricted by poor drug loading and nonspecific distribution. In this study, we developed an inflammatory microenvironment-responsive nanocomplex (IFXSS@HA or IFXTK@HA) for oral administration of Infliximab (IFX) for IBD treatment using self-crosslinking technology, which was developed by reactive oxygen species-responsive cross-linkers and fabricated with hyaluronic acid. The nanocomplex is a "carrier-free" antibody backpack with a high drug loading (>90%), inflammation targeting, and bioresponsive controlled release. The results of preliminary in vivo studies indicated that the nanocomplex showed an extended retention time and caused an increased antibody accumulation in the inflamed intestinal tissues based on hyaluronic acid functionalization and responsive controlled release within the inflammation site, exhibiting great efficacy by reducing intestinal inflammation and systemic exposure. This study provided a rational design for an oral delivery system of antibodies, explored the design of the combination of vehicle and functionalization, and showed a strategy for the oral administration of antibodies in IBD treatment.
Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review

Blake Smith,Haylie Smith,Matthew Machini

DOI: https://doi.org/10.7759/cureus.65357

2024-07-25

Cureus

Abstract:Inflammatory bowel disease (IBD) is a medical condition that causes persistent, relapsing inflammation of the gastrointestinal tract. It is an umbrella term encompassing two different conditions: ulcerative colitis (UC) and Crohn's disease (CD). The standard treatment for patients with moderate to severe CD is tumor necrosis factor-α (TNF-α) inhibitors; however, a subset of CD patients face challenges in regard to this disease's treatment. Certain populations of patients with CD may exhibit resistance or develop tolerance to TNF-α inhibitor therapy over time. The recurrent gastrointestinal inflammation associated with CD can severely impact the quality of life and lead to complications for those suffering from this condition. The symptomatic flare-ups these subpopulations continue to experience underscores why such a need for alternative therapies is desperately needed. These alternative therapies not only offer potential benefits for those with TNF-α resistance, but CD may also serve as a superior therapy option for those trying to avoid the adverse effects of CD treatments available today. This review aims to explore and investigate the novel drugs and therapies that are being investigated for the treatment of TNF-α resistant CD, such as upadacitinib, risankizumab, vedolizumab, synbiotics, fecal microbiota transplantation (FMT), and stem cell therapy. Upadacitinib is a Janus kinase inhibitor, Risankizumab is a monoclonal antibody targeting interleukin-23, and Vedolizumab is an integrin receptor antagonist. The latest advancements in CD management have shown encouraging results. Some of these novel drugs and therapies not only offer a potential solution for CD patients exhibiting resistance to TNF-α inhibitors but may also provide a superior alternative for individuals prone to opportunistic infections.
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis

L. Peyrin-Biroulet,P. Bossuyt,D. Bettenworth,E. V. Loftus,S. I. Anjie,G. D’Haens,M. Saruta,P. Arkkila,H. Park,D. Choi,D- H. Kim,W. Reinisch

DOI: https://doi.org/10.1007/s10620-023-08252-1

2024-03-20

Digestive Diseases and Sciences

Abstract:Infliximab and vedolizumab are widely used to treat Crohn's disease (CD) and ulcerative colitis (UC).

gastroenterology & hepatology
Anti-TNF-α Agents in the Treatment of Crohn's Disease: A Systematic Review

Jinging LIAN,Lijia DING,Shiyao CHEN,Hongchun LIU

DOI: https://doi.org/10.3969/j.issn. 1008-7125.2009.10.006

2009-01-01

Abstract:Background: Up to now, there has been no effective treatment to cure Crohn's disease (CD), the advent of anti-tumor necrosis factor-α (TNF-α) agents has brought the patients a new option. Aims: To systematically evaluate the efficacy and safety of anti-TNF-α agents in the treatment of CD. Methods: Electronic database including MEDLINE/PubMed, OVID, Elsevier ScienceDirect, ISI Web of Knowledge, Cochrane Central Register of Controlled Trials, CBM, CNKI and VIP were retrieved. Besides, the references of articles retrieved and abstracts of some important conferences were also searched manually. Only randomized controlled trials (RCT) of anti-TNF-α agent therapy for CD were included. The quality of selected articles was assessed by Jadad scale and meta-analysis was conducted using RevMan 4.2 software. Results: Fifteen RCTs articles with high quality (Jadad score ≥3) were selected for this study. Compared with placebo, anti-TNF-α agents achieved significantly higher rates of clinical response (44.9% vs. 30.0%, RR=1.39, 95% CI: 1.16-1.67, P=0.0004) and clinical remission (29.3% vs. 18.7%, RR=1.63, 95% CI: 1.26-2.09, P=0.0001). The difference in fistula closure rate between these two groups was also significant (40.6% vs. 25.2%, RR=1.74, 95% CI: 1.23-2.45, P=0.002). Subgroup analysis showed that, both in induction therapy and maintenance therapy, the clinical response rate and remission rate in treatment group were higher than those in placebo group. Rates of adverse events were similar in treatment group and placebo group (77.0% vs. 75.5%, RR=1.01, 95% CI: 0.96-1.07, P=0.57), so as the rates of serious adverse events (11.6% vs. 12.6%, RR=0.87, 95% CI: 0.73-1.04, P=0.13). Conclusions: Anti-TNF-α agents are superior to placebo in the treatment of CD and have similar risks of adverse events and serious adverse events. Long-term trials with large samples are needed for the assessment of its safety and tolerance.

The present and prospective situation of infliximab in treatment of Crohn's disease

Biologic Therapy of Crohn’s Disease: Infliximab

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

Preliminary Study on Treatment of Crohn's Disease with Infliximab

Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature

Safety of Infliximab During Perioperative Period in Crohn Disease Patients

Infliximab in the Treatment of Crohn's Disease: A User's Guide for Clinicians

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease

P-030 Infliximab and Tuberculosis Infection

Crohn’s Disease with Infliximab Treatment Complicated by Rapidly Progressing Colorectal Cancer: A Case Report

Application and Development of Anti-Tumor Necrosis Factor Therapies in Crohn Disease

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Different Therapeutic Approaches on Quality of Life in Patients with Inflammatory Bowel Disease

Infliximab Monotherapy for Chinese Patients with Moderate to Severe Plaque Psoriasis: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial.

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

Optimized timing of using infliximab in perianal fistulizing Crohn's disease

Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease

Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review

Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis

Anti-TNF-α Agents in the Treatment of Crohn's Disease: A Systematic Review